I'm guessing you're talking about the drug LYT-100 which is a MAP kinase inhibitor. As I noted in a previous post it would affect the complement pathway, but not the classical or alternative. It should lower some of the effects of longhaulers but having a lesser downregulation of cytokines I doubt it can stop longhaulers as leronlimab may be able to do.